207 related articles for article (PubMed ID: 38174935)
1. Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and evade antibody recognition.
Casiano Matos J; Harichandran K; Tang J; Sviridov DO; Sidoti Migliore G; Suzuki M; Olano LR; Hobbs A; Kumar A; Paskel MU; Bonsignori M; Dearborn AD; Remaley AT; Marcotrigiano J
J Virol; 2024 Jan; 98(1):e0084923. PubMed ID: 38174935
[TBL] [Abstract][Full Text] [Related]
2. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
3. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
[TBL] [Abstract][Full Text] [Related]
4. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
[TBL] [Abstract][Full Text] [Related]
5. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
Fauvelle C; Felmlee DJ; Crouchet E; Lee J; Heydmann L; Lefèvre M; Magri A; Hiet MS; Fofana I; Habersetzer F; Foung SK; Milne R; Patel AH; Vercauteren K; Meuleman P; Zeisel MB; Bartenschlager R; Schuster C; Baumert TF
Gastroenterology; 2016 Jan; 150(1):206-217.e4. PubMed ID: 26404951
[TBL] [Abstract][Full Text] [Related]
7. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
Rafique S; Idrees M; Ali A; Iqbal M
Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.
Mazumdar B; Banerjee A; Meyer K; Ray R
Hepatology; 2011 Oct; 54(4):1149-56. PubMed ID: 21735466
[TBL] [Abstract][Full Text] [Related]
9. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
[TBL] [Abstract][Full Text] [Related]
10. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
[TBL] [Abstract][Full Text] [Related]
11. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
Urbanowicz RA; Wang R; Schiel JE; Keck ZY; Kerzic MC; Lau P; Rangarajan S; Garagusi KJ; Tan L; Guest JD; Ball JK; Pierce BG; Mariuzza RA; Foung SKH; Fuerst TR
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651366
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
[TBL] [Abstract][Full Text] [Related]
13. Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.
Kong L; Kadam RU; Giang E; Ruwona TB; Nieusma T; Culhane JC; Stanfield RL; Dawson PE; Wilson IA; Law M
J Mol Biol; 2015 Aug; 427(16):2617-28. PubMed ID: 26135247
[TBL] [Abstract][Full Text] [Related]
14. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
[TBL] [Abstract][Full Text] [Related]
15. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.
Catanese MT; Graziani R; von Hahn T; Moreau M; Huby T; Paonessa G; Santini C; Luzzago A; Rice CM; Cortese R; Vitelli A; Nicosia A
J Virol; 2007 Aug; 81(15):8063-71. PubMed ID: 17507483
[TBL] [Abstract][Full Text] [Related]
16. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
17. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
[TBL] [Abstract][Full Text] [Related]
18. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
mBio; 2017 May; 8(3):. PubMed ID: 28512091
[TBL] [Abstract][Full Text] [Related]
19. Syntenin regulates hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.
Deng L; Jiang W; Wang X; Merz A; Hiet MS; Chen Y; Pan X; Jiu Y; Yang Y; Yu B; He Y; Tu Z; Niu J; Bartenschlager R; Long G
J Hepatol; 2019 Jul; 71(1):52-61. PubMed ID: 30880226
[TBL] [Abstract][Full Text] [Related]
20. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
Bose M; Mullick R; Das S; Das S; Karande AA
Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
